Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.

ABSTRACT:

Unlabelled

Molecular mechanisms of lapatinib resistance in breast cancer are not well understood. The aim of this study was to correlate expression of selected proteins involved in ErbB family signaling pathways with clinical efficacy of lapatinib. Study group included 270 HER2-positive advanced breast cancer patients treated with lapatinib and capecitabine. Immunohistochemical expression of phosphorylated adenosine monophosphate-activated protein (p-AMPK), mitogen-activated protein kinase (p-MAPK), phospho (p)-p70S6K, cyclin E, phosphatase and tensin homolog were analyzed in primary breast cancer samples. The best discriminative value for progression-free survival (PFS) was established for each biomarker and subjected to multivariate analysis. At least one biomarker was determined

SUBMITTER: Duchnowska R 

PROVIDER: S-EPMC4808017 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature